within Pharmacolibrary.Drugs.ATC.B;

model B06AA10
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B06AA10</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Desoxyribonuclease (also known as DNase or Dornase alfa) is an enzyme that hydrolyzes DNA and is primarily used to reduce the viscosity of sputum in patients with cystic fibrosis, facilitating mucociliary clearance. It is currently approved and used for this indication.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies in humans providing detailed PK parameters (volume of distribution, clearance, etc.) could be identified. Dornase alfa is known to be administered via inhalation, acting locally in the lungs with minimal systemic absorption in adults and children with cystic fibrosis.</p><h4>References</h4><ol><li><p>Liu, C, et al., &amp; Zheng, Y (2023). An Inhalable Hybrid Biomimetic Nanoplatform for Sequential Drug Release and Remodeling Lung Immune Homeostasis in Acute Lung Injury Treatment. <i>ACS nano</i> 17(12) 11626–11644. DOI:<a href=&quot;https://doi.org/10.1021/acsnano.3c02075&quot;>10.1021/acsnano.3c02075</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37285229/&quot;>https://pubmed.ncbi.nlm.nih.gov/37285229</a></p></li><li><p>Witt, DM, &amp; Anderson, L (1996). Dornase alfa: a new option in the management of cystic fibrosis. <i>Pharmacotherapy</i> 16(1) 40–48. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8700791/&quot;>https://pubmed.ncbi.nlm.nih.gov/8700791</a></p></li><li><p>Osman, R, et al., &amp; Alpar, O (2013). Inhalable DNase I microparticles engineered with biologically active excipients. <i>Pulmonary pharmacology &amp; therapeutics</i> 26(6) 700–709. DOI:<a href=&quot;https://doi.org/10.1016/j.pupt.2013.07.010&quot;>10.1016/j.pupt.2013.07.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23933140/&quot;>https://pubmed.ncbi.nlm.nih.gov/23933140</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B06AA10;
